Twenty/Twenty Therapeutics
Twenty/Twenty Therapeutics was a joint venture between Verily Life Sciences and Santen Pharmaceutical. VitreoDx was a central pillar of Twenty/Twenty Therapeutics’ mission to develop transformative innovations to prevent and halt vision loss in patients with macular degeneration.
Twenty/Twenty Therapeutics was a joint venture between Verily Life Sciences, an Alphabet company, and Santen Pharmaceutical, a Japanese ophthalmology company. VitreoDx was a central pillar of Twenty/Twenty Therapeutics’ mission to develop transformative innovations to prevent and halt vision loss in patients with macular degeneration.
